	US 12,186,433 B2
	Nanocapsules comprising modified nucleobases and/or nucleosides, hydrogels and oleogels comprising them and uses thereof
Marion Pitorre, Angers (FR); Guillaume Bastiat, Briollay (FR); Jérôme Bejaud, Angers (FR); and Jean-Pierre Benoit, Angers (FR)
Assigned to Universite D'Angers France, Angers (FR); Institut National De La Sante et de la Recherche Medicale (INSERM), Paris (FR); Centre National de la Recherche Scientifique, Paris (FR); and Centre Hospitalier Universitaire D'Angers Cedex France, Angers (FR)
Appl. No. 16/644,275
Filed by UNIVERSITE D'ANGERS, Angers (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); and CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS, Angers (FR)
PCT Filed Sep. 7, 2018, PCT No. PCT/EP2018/074221 § 371(c)(1), (2) Date Mar. 4, 2020, PCT Pub. No. WO2019/048649, PCT Pub. Date Mar. 14, 2019.
Claims priority of application No. 17306164 (EP), filed on Sep. 8, 2017.
Prior Publication US 2021/0161828 A1, Jun. 3, 2021
Int. Cl. A61K 9/51 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); C07H 19/06 (2006.01); C07H 19/16 (2006.01)

CPC A61K 9/5123 (2013.01) [A61K 9/0019 (2013.01); A61K 9/06 (2013.01); C07H 19/06 (2013.01); C07H 19/16 (2013.01)]

11 Claims

1. A method for treating and/or preventing vascular disease, comprising administering to a mammal in need thereof a therapeutically effective amount of an hydrogel or an oleogel,

wherein said hydrogel comprises nanocapsules, an aqueous phase, and an active ingredient N in an aqueous phase of the hydrogel, said hydrogel having a G″/G′ inferior to 1, and said nanocapsules comprise at least one compound A and have a mean size diameter of less than 150 nm,

wherein said oleogel comprises at least one compound A an oily phase, and an active ingredient P in the oily phase of the oleogel, said oleogel having a G″/G′ ratio inferior to 1,

and wherein said compound A has the following formula (A):

wherein:

B is selected from the group consisting of a nucleobase, a nucleoside, a deoxynucleoside, and one of their derivatives, and

R is a linear or branched, saturated or unsaturated (C₉-C₂₁) alkyl, said alkyl being optionally substituted by one or more substituent(s) selected from the group consisting of:

—COOH, —OH, —SH, —NH₂, —COORa, —ORa, —SRa, and —NRaRb,

with Ra being a linear or branched, saturated or unsaturated (C₁-C₁₀) alkyl, and Rb being H or a linear or branched, saturated or unsaturated (C₁-C₁₀) alkyl, provided that said compound A is not: